ArticleFrontiers in psychiatry2020
Progressive Impairment of Mismatch Negativity Is Reflective of Underlying Pathophysiological Changes in Patients With First-Episode Psychosis.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Predicting ordinal clinical outcomes in at-risk mental states: a multimodal approach.Frontiers in psychiatry · 2026Article
- Mismatch Negativity in Subjects at Clinical High Risk for Psychosis: No Evidence of Progressive Decline.The European journal of neuroscience · 2025Article
- Altered theta band and theta/beta ratio in mismatch negativity associate with treatment effect in schizophrenia with auditory hallucinations.Schizophrenia research. Cognition · 2025Article
- A comparison of visual and acoustic mismatch negativity as potential biomarkers in schizophrenia.Scientific reports · 2024Article
- Mismatch negativity and clinical trajectories in psychotic disorders: Five-year stability and predictive utility.Psychological medicine · 2023Article
- Why mismatch negativity continues to hold potential in probing altered brain function in schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2023Review
- Working memory and sensory memory in subclinical high schizotypy: An avenue for understanding schizophrenia?The European journal of neuroscience · 2023Review
- Unveiling the Associations between EEG Indices and Cognitive Deficits in Schizophrenia-Spectrum Disorders: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough mismatch negativity (MMN) is associated with the pathophysiology of schizophrenia, whether MMN progressively worsens during the initial years of psychotic disorder has not yet been sufficiently studied. We aimed to investigate whether longitudinal reduction of MMN occurs in patients with first-episode psychosis (FEP) and whether it is reflective of change in cognitive functioning or clinical status.
methodsMMN and the clinical status of 25 patients with FEP were measured and the Trail Making Test (TMT) was administered at baseline and reassessed after 1 year of usual treatment. The MMN of 25 matched healthy controls (HCs) was measured at baseline. Repeated-measures analysis of variance was used to compare MMNs at baseline among the groups, and paired t-test was utilized to compare the baseline and 1-year MMN amplitudes of FEP patients. To identify the association between changes in MMN and changes in cognitive, symptomatic, or functional status over 1 year, multiple regression analysis was used to control for other possible confounders.
resultsMMN amplitudes at baseline were significantly attenuated in FEP patients compared to those in HC. The 1-year follow-up MMN amplitude decreased significantly at the Fz electrode site in the FEP group. Additionally, the decreased MMN amplitude significantly correlated with worsened TMT part B (TMT-B) performance over 1 year but did not correlate with symptomatic or functional improvement.
conclusionsFEP patients with an MMN amplitude reduction showed worsening of cognitive functioning, which might reflect pathophysiological progression during the early years of a psychotic episode.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.